Novartis announces Oncology head to retire
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program
Business Wire, 12.12.2017
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link.
Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia
Business Wire, 12.12.2017
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies' previously announced collaboration aimed at the discovery and development of new gene editing treatments that use the CRISPR/Cas9 technology. CTX001 represents the first gene-based treatment that Vertex exclusively licensed from CRISPR Therapeutics as part of the collaboration. For CTX001, CRISPR and Vertex will equally share all research and development costs and profits worldwide. A Clinical Trial Application was submitted earlier this month for CTX001 to support the initiation of a Phase 1/2 trial in β-thalassemia in 2018 in Europe, and an Investigational New Drug (IND) Application is planned for submission in 2018 to support the initiation of a Phase 1/2 trial in sickle cell disease in the U.S. Preclinical data presented for CTX001 at the American Society for Hematology on December 10, 2017 showed clinically relevant increases in fetal hemoglobin and a high editing rate that support the advancement of CTX001 into the planned trials in β-thalassemia and sickle cell disease in 2018.
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301
SBA Member, 12.12.2017
Lausanne, Switzerland, December 11, 2017 - ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or "Cami-T") in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA.
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017
Novartis tender offer for Advanced Accelerator Applications commences
Clinerion and iHealth Group partner with Bioserv SMO to accelerate clinical research in Brazil by introducing Clinerion’s PRS to the Hospital São Vicente de Paulo.
In concert with its Brazilian partner, the iHealth Group, Clinerion has agreed with Bioserv SMO to add Bioserv’s trial sites to the PRS platform. The Hospital São Vicente de Paulo is the first implementation, bringing another 540 thousand patient lives to Clinerion’s coverage in Brazil.
Bioserv SMO manages trial sites in the Rio Grande do Sul region of Brazil. The first implementation of PRS will take place at the Hospital São Vicente de Paulo, in the city of Passo Fundo. São Vicente de Paulo has 600 beds, and its hospital information system holds 540K patient lives.
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
Abionic Announces Appointment of Leading Diagnostics Industry Experts to Board of Directors
Business Wire, 06.12.2017
Abionic SA, a developer of disrupter nanotechnology based rapid diagnostic solutions, announced today the appointment of two diagnostic industry experts, Dr. Gerd Grenner and Nader Donzel, to its Board of Directors.
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
Helsinn Group supports Satellite Symposium at 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting
Idorsia announces collaboration with Janssen Biotech on aprocitentan (ACT-132577)
- Idorsia to receive milestone payment of USD 230 million
Idorsia and Janssen Biotech to share costs of Phase 3 development equally
Idorsia entitled to royalty payments on potential future net sales
AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases
SBA Member, 03.12.2017
Lausanne, Switzerland, December 1, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, shared the top level insights from today's Key Opinion Leader (KOL) luncheon meeting on the importance of Tau as a target in Alzheimer's disease and other neurodegenerative diseases. The meeting featured presentations by KOLs Khalid Iqbal, PhD (New York State Institute for Basic Research in Developmental Disabilities) and Michael Rafii, MD, PhD (UC San Diego and USC).
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
Basilea eligible to receive additional upfront and milestone payments of up to USD 226 million and mid-teen royalties on sales
Basilea updates its financial guidance for 2017 - improved result expected
Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Tillotts Pharma Successfully Completes DCP1 for Colpermin™ in Europe
SBA Member, 29.11.2017
RHEINFELDEN, Switzerland, Nov. 29 2017 – Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, today announced that the German Federal Institute for Drugs and Medical Devices (BfArM) has closed the decentralised authorisation procedure (DCP) for Colpermin™ (peppermint oil), an over-the-counter2 (OTC) antispasmodic already marketed in Switzerland. Under this procedure, Colpermin was simultaneously authorised in a number of Member States3 of the European Union (EU).
NBE-Therapeutics Appoints Dr. Nicole Onetto to Its Board of Directors
SBA member, 28.11.2017
Basel, Switzerland, November 28, 2017 / B3C newswire / -- Today NBE Therapeutics AG, a biopharmaceutical company developing next-generation antibody drug conjugates (ADCs) carrying highly potent, immune-stimulatory anthracycline toxins, announces the appointment of Dr. Nicole Onetto to its Board of Directors.
BIOPOLE APPOINTS MEMBERS OF STARTLAB ADVISORY BOARD AND ANNOUNCES FIRST CANDIDATES SELECTED FOR STARTLAB INCUBATOR
- Appointments made to StartLab Advisory Board
- First candidates – HaYa Therapeutics and GNUbiotics – selected for dedicated life sciences incubator
- Plug and play facilities to open in spring 2018
- Focus on high quality startups to enrich dynamic Swiss ecosystem
Ferring receives Swiss approval for Rekovelle®, the first personalised fertility treatment using an approved dosing algorithm
- Rekovelle® provides doctors with an approved, evidence-based, individualised dosing regimen to personalise fertility treatment
- Approval expands options for fertility patients in Switzerland, providing a new and tailored approach to help doctors achieve target ovarian response
- Approval is based on a comprehensive clinical development programme (ESTHER), involving patients in 11 countries and over 2,000 treatment cycles
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
Top European Biotech SMEs announced at 8th edition of EuropaBio Awards
AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases
SBA Member, 22.11.2017
Lausanne, Switzerland, November 21, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will host a Key Opinion Leader (KOL) luncheon meeting on the importance of Tau as a target in Alzheimer's disease and other neurodegenerative diseases on December 1, 2017 from 12.00pm - 1.45pm ET at the St. Regis Hotel, 2 E. 55th Street in New York, NY.
EuropaBio statement regarding the re-location of the EMA to Amsterdam
EuropaBio and its members welcome the decision of the European Council to provide clarity on the relocation of the European Medicines Agency (EMA) to Amsterdam, ending a prolonged period of uncertainty and speculation around the future location for patients, the EMA agency staff and industry.
“Now that we have more clarity, it is vital that the relocation of the EMA will be carried out in such a way as to minimise as much as possible any disruptions that could negatively affect access to medicines for patients”, said John Brennan, EuropaBio Secretary General.